With PPV of 0.39 [0.31–0.58] and NPV of 0.95 [0.92–0.98], p217+tau effectively excluded Advanced stage AD when below the Youden threshold, but did not accurately predict Advanced stage when above, due to the inclusion of many Intermediate stage AD participants. The gene discussed is MAPT; the disease is Alzheimer disease.